Merck stock analysis: great pipeline at a stretched valuation

Merck (MRK) stock rose 3.4% to a 52-week high of $154.49 after positive Phase 3 trial results for its cancer vaccine. Analysts upgraded MRK and raised price targets, citing long-term growth prospects. Broader market gains were modest but supportive. Sector peers also gained on renewed confidence in mRNA technology.

Moderna's shares surged 176.97% after it and Merck announced their experimental vaccine-drug treatment slowed melanoma recurrence in a late-stage trial. The treatment combines Moderna's mRNA vaccine with Merck's Keytruda. Analysts' reactions were mixed, with some advising caution and others seeing significant potential. Moderna and Merck reported revenue declines and gains, respectively. Short sellers faced substantial losses.

Moderna and Merck reported positive Phase 3 trial results for a personalized mRNA cancer vaccine combined with Keytruda, showing a 49% improvement in recurrence risk for melanoma. Moderna's stock surged 177% before partially retracing. Analysts question the technology's broader applicability and data specifics, set to be released in October. The treatment could generate $5.4B in sales by 2040 if approved, according to William Blair.

Moderna and Merck reported success in a large-scale trial of their personalized cancer vaccine for melanoma, meeting primary targets. The treatment, combining Moderna's vaccine with Merck's pembrolizumab, showed reduced cancer recurrence. Both companies are in talks with regulators, with potential availability as early as next year. Moderna's shares surged, adding nearly $40bn to its market cap. Merck also climbed 12%. Trials for other cancer types are ongoing.

Moderna and Merck's personalized cancer vaccine, intismeran autogene, showed success in a Phase 3 melanoma trial, reducing recurrence risk. The treatment, tailored to each patient's tumor mutations, was combined with Merck's Keytruda. Both companies plan further studies in other cancers. BioNTech and Roche are developing a similar treatment. Full trial data and long-term survival results are pending.

Moderna and Merck's experimental mRNA cancer vaccine, intismeran, showed promise in a phase 3 trial for high-risk melanoma patients. The personalized vaccine, combined with Keytruda, aims to train the immune system to target cancer cells. Early results indicate extended cancer-free periods, but long-term effects are unclear. Trials for lung, bladder, and kidney cancers are also underway.